Hcw Biologics INC. (HCWB) — SEC Filings

Overview

Hcw Biologics INC. (HCWB) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-1/A filed on Apr 24, 2026: HCW Biologics Inc. filed an S-1/A amendment on April 24, 2026, related to its registration of securities under the Securities Act of 1933. The filing, with accession number 0001493152-26-018992, includes a 772,245-byte S-1/A document and other related files. The company's mailing and business addres

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 8 bearish, 42 neutral. The dominant filing sentiment for Hcw Biologics INC. is neutral.

Filing Type Overview

Hcw Biologics INC. (HCWB) has filed 2 S-1/A, 3 S-1, 35 8-K, 5 10-Q, 2 DEF 14A, 1 10-K, 1 SC 13D/A, 1 8-K/A with the SEC between Jun 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• HCW Biologics Files S-1/A Amendment — S-1/A · Apr 24, 2026 Risk: medium
  HCW Biologics Inc. filed an S-1/A amendment on April 24, 2026, related to its registration of securities under the Securities Act of 1933. The filing, with acce
• S-1 Filing — S-1 · Apr 23, 2026
• 8-K Filing — 8-K · Dec 31, 2025
• HCW Biologics Files 8-K: Material Agreement & Equity Sales — 8-K · Nov 20, 2025 Risk: medium
  HCW Biologics Inc. announced on November 19, 2025, that it entered into a material definitive agreement. The company also disclosed unregistered sales of equity
• HCW Biologics Enters Material Definitive Agreement — 8-K · Nov 19, 2025 Risk: medium
  HCW Biologics Inc. entered into a material definitive agreement on November 17, 2025. The filing does not disclose specific details of the agreement, such as th
• 8-K Filing — 8-K · Nov 18, 2025
• HCWB's Revenue Plummets Amidst License Suspension, Debt Restructuring — 10-Q · Nov 14, 2025 Risk: high
  HCW Biologics Inc. (HCWB) reported a significant increase in net loss for the three months ended September 30, 2025, reaching $4,554,336, up from $3,902,288 in
• HCW Biologics Faces Delisting Notice — 8-K · Oct 16, 2025 Risk: high
  HCW Biologics Inc. filed an 8-K on October 16, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, effective Octob
• HCW Biologics Enters Material Definitive Agreement — 8-K · Sep 5, 2025 Risk: medium
  HCW Biologics Inc. announced on September 2, 2025, that it entered into a material definitive agreement. The filing does not provide specific details about the
• HCW Biologics Faces Delisting Concerns — 8-K · Aug 19, 2025 Risk: high
  HCW Biologics Inc. filed an 8-K on August 19, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The company is i
• HCW Biologics Files Q2 2025 10-Q — 10-Q · Aug 18, 2025 Risk: medium
  HCW Biologics Inc. filed its 10-Q for the period ending June 30, 2025. The filing details various financial activities, including transactions related to conver
• HCW Biologics Files 8-K for Material Agreement — 8-K · Aug 15, 2025 Risk: medium
  HCW Biologics Inc. filed an 8-K on August 15, 2025, reporting an entry into a material definitive agreement on August 14, 2025. The filing also includes financi
• HCW Biologics Files 8-K on Financials — 8-K · Aug 14, 2025 Risk: low
  HCW Biologics Inc. filed an 8-K on August 14, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and
• HCW Biologics Enters Material Definitive Agreement — 8-K · Jul 18, 2025 Risk: medium
  HCW Biologics Inc. announced on July 14, 2025, that it entered into a material definitive agreement. The filing does not disclose specific details of the agreem
• HCW Biologics Files 8-K for Other Event — 8-K · Jul 1, 2025 Risk: medium
  HCW Biologics Inc. filed an 8-K on June 18, 2025, reporting an 'Other Event'. The filing does not provide specific details about the event itself, only that it
• HCW Biologics Files 8-K: Other Events & Financials — 8-K · Jun 26, 2025 Risk: medium
  HCW Biologics Inc. filed an 8-K on June 26, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific details
• HCW Biologics Files 8-K: Director/Officer Changes & Shareholder Votes — 8-K · Jun 23, 2025 Risk: medium
  HCW Biologics Inc. filed an 8-K on June 23, 2025, reporting events as of June 17, 2025. The filing covers the departure and election of directors, appointment o
• HCW Biologics Files 8-K for Other Events — 8-K · Jun 13, 2025 Risk: low
  HCW Biologics Inc. filed an 8-K on June 13, 2025, reporting an event that occurred on June 12, 2025. The filing pertains to 'Other Events' and does not specify
• HCW Biologics Files 8-K: Routine Update — 8-K · Jun 5, 2025 Risk: low
  HCW Biologics Inc. filed an 8-K on June 5, 2025, reporting other events and financial statements. The filing details the company's principal executive offices l
• HCW Biologics Inc. Files 8-K with Material Agreement — 8-K · Jun 4, 2025 Risk: medium
  On May 29, 2025, HCW Biologics Inc. entered into a material definitive agreement. The company also reported on other events and filed financial statements and e
• HCW Biologics Files 8-K for Other Events — 8-K · May 30, 2025 Risk: medium
  HCW Biologics Inc. filed an 8-K on May 30, 2025, reporting an event on May 28, 2025. The filing indicates 'Other Events' as the item information, with no specif
• HCW Biologics Files 8-K: Other Events — 8-K · May 23, 2025 Risk: medium
  On May 21, 2025, HCW Biologics Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events." No specific detail
• HCW Biologics Files 8-K for Other Events — 8-K · May 20, 2025 Risk: low
  HCW Biologics Inc. filed an 8-K on May 20, 2025, reporting an event that occurred on May 15, 2025. The filing pertains to 'Other Events' and does not specify an
• HCW Biologics Files Q1 2025 10-Q, Reports Subsequent Events — 10-Q · May 15, 2025 Risk: medium
  HCW Biologics Inc. filed its Q1 2025 10-Q report on May 15, 2025, detailing operations for the period ending March 31, 2025. The company's business address is 2
• HCW Biologics Files S-1/A Amendment — S-1/A · May 13, 2025 Risk: medium
  HCW Biologics Inc. filed an S-1/A on May 13, 2025, as Pre-Effective Amendment No. 1 to its Form S-1 Registration Statement. The filing, with registration number
• HCW Biologics Files S-1 for IPO — S-1 · May 9, 2025 Risk: medium
  HCW Biologics Inc. filed an S-1 registration statement on May 9, 2025, for its initial public offering. The company, based in Miramar, Florida, is in the pharma
• HCW Biologics Files 2025 Proxy Statement — DEF 14A · Apr 28, 2025 Risk: low
  HCW Biologics Inc. filed its definitive proxy statement on April 28, 2025, for its 2025 Annual Meeting of Stockholders scheduled for June 17, 2025. The company,
• HCW Biologics Files 8-K Under 'Other Events' — 8-K · Apr 22, 2025 Risk: medium
  HCW Biologics Inc. filed an 8-K on April 22, 2025, reporting an event that occurred on April 17, 2025. The filing is categorized under 'Other Events' and does n
• HCW Biologics Files 8-K: Material Agreement & Financials — 8-K · Apr 14, 2025 Risk: medium
  HCW Biologics Inc. filed an 8-K on April 14, 2025, reporting an entry into a material definitive agreement and other events. The filing also includes financial
• HCW Biologics Files S-1 for Public Offering — S-1 · Apr 7, 2025 Risk: medium
  HCW Biologics Inc. filed an S-1 registration statement on April 7, 2025, to register securities for public sale. The company, based in Miramar, FL, is in the ph
• HCW Biologics Files 8-K on Corporate Matters — 8-K · Apr 1, 2025 Risk: low
  HCW Biologics Inc. filed an 8-K on April 1, 2025, reporting on matters submitted to a vote of security holders and other events. The filing details the company'
• 10-K Filing — 10-K · Mar 28, 2025
• HCW Biologics Enters Material Definitive Agreement — 8-K · Mar 19, 2025 Risk: medium
  HCW Biologics Inc. announced on March 17, 2025, that it entered into a material definitive agreement. The filing does not provide specific details about the agr
• HCW Biologics Faces Delisting Concerns — 8-K · Mar 6, 2025 Risk: high
  HCW Biologics Inc. filed an 8-K on March 6, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The filing also includes finan
• HCW Biologics Schedules Special Stockholder Meeting — DEF 14A · Feb 21, 2025 Risk: low
  HCW Biologics Inc. filed a definitive proxy statement (DEF 14A) on February 21, 2025, for a special meeting of stockholders scheduled for March 31, 2025. The fi
• HCW Biologics Enters Material Definitive Agreement — 8-K · Feb 21, 2025 Risk: medium
  HCW Biologics Inc. announced on February 20, 2025, that it entered into a material definitive agreement. The filing does not disclose specific details of the ag
• HCW Biologics Faces Delisting Concerns — 8-K · Feb 7, 2025 Risk: high
  HCW Biologics Inc. filed an 8-K on February 7, 2025, reporting a notice of delisting or failure to satisfy continued listing rules. The company is also reportin
• HCW Biologics Files 8-K — 8-K · Feb 3, 2025 Risk: low
  HCW Biologics Inc. filed an 8-K on February 3, 2025, to report information under Regulation FD Disclosure and Financial Statements and Exhibits. The filing does
• HCW Biologics Faces Delisting Concerns — 8-K · Dec 23, 2024 Risk: high
  HCW Biologics Inc. filed an 8-K on December 23, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of December
• Hing C. Wong Amends HCW Biologics Stake Filing — SC 13D/A · Nov 22, 2024 Risk: medium
  Hing C. Wong, through HCW Biologics Inc., filed an amendment (No. 1) to their Schedule 13D on November 22, 2024, regarding their holdings in HCW Biologics Inc.
• HCW Biologics Files 8-K: Material Agreement & Equity Sales — 8-K · Nov 20, 2024 Risk: medium
  HCW Biologics Inc. announced on November 18, 2024, that it entered into a Material Definitive Agreement. The company also disclosed unregistered sales of equity
• HCW Biologics Inc. Enters Material Definitive Agreement — 8-K · Nov 18, 2024 Risk: medium
  On November 18, 2024, HCW Biologics Inc. entered into a material definitive agreement and created a direct financial obligation. The specific details of this ag
• HCW Biologics Files Q3 2024 10-Q — 10-Q · Nov 14, 2024 Risk: medium
  HCW Biologics Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial position and operational highlights. Key financia
• HCW Biologics Changes Independent Auditor — 8-K · Sep 20, 2024 Risk: medium
  HCW Biologics Inc. announced on September 20, 2024, a change in its certifying accountant. The company has dismissed PricewaterhouseCoopers LLP and engaged With
• HCW Biologics Files 8-K/A Amendment — 8-K/A · Aug 23, 2024 Risk: low
  HCW Biologics Inc. filed an 8-K/A on August 23, 2024, to amend a previous filing concerning the results of operations and financial condition as of August 14, 2
• HCW Biologics Files Q2 2024 10-Q, Appoints New EVP — 10-Q · Aug 14, 2024 Risk: medium
  HCW Biologics Inc. reported its financial results for the quarter ended June 30, 2024. The company's filing details its financial position, including assets lik
• HCW Biologics Faces Delisting Concerns — 8-K · Aug 12, 2024 Risk: high
  HCW Biologics Inc. filed an 8-K on August 12, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The earliest eve
• HCW Biologics Enters Material Definitive Agreement — 8-K · Jul 18, 2024 Risk: medium
  HCW Biologics Inc. announced on July 18, 2024, that it entered into a material definitive agreement. The filing does not disclose specific details of the agreem
• HCW Biologics Faces Delisting Notice — 8-K · Jun 20, 2024 Risk: high
  HCW Biologics Inc. filed an 8-K on June 20, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of June 17, 2024
• HCW Biologics Files 8-K on Shareholder Votes — 8-K · Jun 17, 2024 Risk: low
  HCW Biologics Inc. filed an 8-K on June 17, 2024, reporting on matters submitted to a vote of security holders as of June 14, 2024. The filing details the compa

Risk Profile

Risk Assessment: Of HCWB's 46 recent filings, 8 were flagged as high-risk, 28 as medium-risk, and 10 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Hcw Biologics INC.'s most recent 10-Q filing (Nov 14, 2025):

• Revenue: $15,606
• Net Income: -$4,554,336
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: $1,096,909
• Operating Margin: N/A
• Total Assets: $25,445,540
• Total Debt: $26,860,206

Key Executives

• Scott T. Garrett
• Hing C. Wong
• Hing C. Wong, Ph.D.
• James Groth
• Randolf Katz
• Barry I. Grossman, Esq.
• Matthew Berns
• Dr. Wong
• Mr. Garrett

Industry Context

HCW Biologics operates in the highly competitive and capital-intensive biopharmaceutical sector, focusing on developing novel immunotherapies. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Companies often rely on strategic partnerships and substantial funding to advance drug candidates through clinical trials and towards commercialization.

Top Tags

material-agreement (12) · delisting (7) · regulatory-filing (6) · 8-K (6) · sec-filing (5) · biotech (5) · financials (5) · amendment (4) · listing-standards (4) · 10-Q (4)

Key Numbers

• S-1/A Document Size: 772245 — Indicates the size of the primary registration document filed.
• GRAPHIC File Size: 2672 — Size of the graphic file included in the submission.
• Complete Submission Text File Size: 777045 — Size of the full text submission file.
• SEC File Number: 001-40591 — Identifies the company's filing with the SEC.
• IRS Employer Identification No.: 82-5024477 — Company's tax identification number.
• Net Loss (Q3 2025): $4,554,336 — Increased from $3,902,288 in Q3 2024, indicating worsening profitability.
• Revenue (Q3 2025): $15,606 — Drastically down from $426,423 in Q3 2024, primarily due to Wugen license suspension.
• Cash and Cash Equivalents (Sept 30, 2025): $1,096,909 — Significantly reduced from $4,674,572 at Dec 31, 2024, highlighting liquidity concerns.
• Cumulative Net Losses: $106.5 million — Since inception to September 30, 2025, indicating a history of unprofitability.
• Reverse Stock Split Ratio: 1:40 — Effective April 11, 2025, to increase per-share price.
• Debt Extinguished: $7.7 million — Through restructuring or conversion during the nine months ended September 30, 2025.
• Short-term Debt (Cogent Bank): $6.2 million — Remaining balance of loan, now subject to discretionary default and acceleration.
• Net Cash Used in Operating Activities (9M 2025): $10,036,100 — Continued negative operating cash flow, though an improvement from $11,392,547 in 9M 2024.
• Commission File Number: 001-40591 — Identifies the company's SEC filing history.
• End of Reporting Period: 20250630 — This is the end date for the financial data presented in the 10-Q.

Frequently Asked Questions